Intracranial Biomarkers for Anterior Thalamic Deep Brain Stimulation in Epilepsy: a long-term observational study

Deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) is an established treatment for patients with drug-refractory epilepsy (DRE), yet long-term therapeutic outcomes are highly variable and challenging to predict. This variability is compounded by the delayed and gradual effects of DBS, the difficulty of consistent seizure monitoring, and the absence of physiological biomarkers to inform treatment. In this study, we analyzed longitudinal intracranial recordings over a four-year observational period from a cohort of 22 patients with ANT-DBS. Our primary goal is the identification of neurophysiological signatures that could predict and track clinical DBS response. Our results show that DBS-responders and non-responders exhibit distinct ANT spectral trajectories over time, with responders showing a progressive increase in higher frequencies ({beta}1,{gamma} ) and decreased lower-frequency ({delta}, {theta}) activity, as compared to non-responders. Notably, these dynamic biomarkers, particularly high-to-low frequency ratios (e.g., {beta}1/{theta}), enabled the early discrimination of clinical outcomes. Additionally, we provide evidence of robust circadian and multidien rhythms in ANT local field potentials, with further analyses supporting the feasibility of adaptive stimulation protocols to improve therapeutic outcomes. Together, these findings propose ANT spectral dynamics in outpatient settings as a promising tool for early prediction of therapeutic efficacy and pave the way for biomarker-guided optimization of DBS therapy in epilepsy. HighlightsO_LILongitudinal analysis of spectral activity evolution in the anterior thalamic nucleus (ANT) revealed different temporal dynamics in responders and non-responders to ANT-Deep Brain Stimulation (DBS). C_LIO_LIHigh-to-low frequency power ratios (e.g., {beta}1/{theta}) enable discrimination between super-responders and non-responders for assessing therapeutic efficacy, offering a potential tool for early therapy evaluation. C_LIO_LIANT activity exhibits circadian and multidien fluctuations, reinforcing its potential as a signal source for adaptive DBS strategies tailored to individual brain states. C_LI